Ascenion’s portfolio company OMEICOS dosed a first patient in a Phase II clinical trial for its lead program OMT-28. The placebo-controlled, double-blind, randomized PROMISE-AF study will evaluate the efficacy and safety of the candidate in patients with persistent atrial fibrillation (AF). In total, the company expects to enrol up to 120 participants in four European countries.
OMT-28, a synthetic small molecule analogue of a natural omega-3 fatty acid metabolite, targets one of nature’s most important cell-protective pathways. If successful, it would introduce a novel treatment modality in the segment of anti-arrhythmic drugs, with potential benefits for millions of patients.
For further information see OMEICOS’ press release